E1912 A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia

Cancer - Leukemia, Cancer
Syed Ali, MD

  D’Amour Center for Cancer Care

3350 Main Street

Springfield MA 01199


Franklin Medical Center

164 High Street

Greenfield MA

The purpose of this study is to compare the effects, good and/or bad, of two different therapies that include combinations of the drugs rituximab, fludarabine, cyclophosphamide and Ibrutinib
Diagnosis of Chronic Lymphocytic Leukemia not previously treated
Katie Colbeck